PD-L1 Antibody (Hu124) [Unconjugated]

MDA-MB-231 human breast adenocarcinoma cell line was stained with Human Anti-Human PD-L1/B7-H1 (Research Grade Atezolizumab Biosimilar) Monoclonal Antibody (Catalog # MAB10348, filled histogram) or irrelevant antibody (open histogram) followed by APC-conjugated Anti-Human IgG Secondary Antibody (F0135). View our protocol for Staining Membrane-associated Proteins.

In a functional flow cytometry test, Recombinant Human PD-1 His-tagged protein (8986-PD, 500 ng/mL) binds to HEK293 human embryonic kidney cell line transfected with recombinant human PD-L1/B7-H1. (A) Binding is completely blocked by 2.5 µg/mL of Human Anti-Human PD-L1/B7-H1 (Research Grade Atezolizumab Biosimilar) Monoclonal Antibody (Catalog # MAB10348) but not by (B) Human IgG Isotype Control (1-001-A). Ligand binding was detected by staining cells with Anti-His tag APC-conjugated Monoclonal Antibody (IC050A).

Biosimilar antibody development at Bio-Techne includes in silico design and engineering to generate both light chain (lc) and heavy chain (hc) sequences for each antibody. After transfection of the dual expression vector, Bio-Techne’s biosimilar antibodies undergo rigorous application testing to ensure the final biosimilar product is suited for your research needs.

• Reactivity: Hu
• Applications: Flow, B/N, CyTOF-ready
• Clone: Hu124
• Clonality: Monoclonal
• Host: Human
• Conjugate: Unconjugated

PD-L1 Antibody (Hu124) [Unconjugated] Summary

• Additional Information: Recombinant Monoclonal Antibody For Research Use Only
• Immunogen: Human PD-L1/B7-H1
• Specificity: Detects Human PD-L1/B7-H1 in direct ELISAs. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Atezolizumab. This product is for research use only.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Human
• Purity Statement: Protein A or G purified from cell culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Blockade of Receptor-ligand Interaction
  • CyTOF-ready
  • Flow Cytometry 0.25 ug/10^6 cells

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for PD-L1 Antibody (Hu124) [Unconjugated]

• Avelumab
• B7-H
• B7H1
• B7-H1
• B7H1PDCD1L1
• CD274 antigenMGC142294
• CD274 molecule
• CD274
• PDCD1L1
• PDCD1LG1
• PDCD1LG1MGC142296
• PDL1
• PD-L1
• PD-L1B7 homolog 1
• PDL1PDCD1 ligand 1
• programmed cell death 1 ligand 1
• Programmed death ligand 1

Background

Atezolizumab is a biosimilar directed against human PD-L1.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.